Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
lower back pain
Biotech
Eli Lilly sidelines pain prospect in another pipeline shift
The asset was originally licensed from Asahi Kasei Pharma in 2021, and Lilly is now exploring other possible indications for the P2X7 inhibitor.
Darren Incorvaia
Oct 30, 2025 2:19pm
Spine BioPharma misses primary endpoint in back pain phase 3
Aug 1, 2025 10:24am
Mainstay Medical merits $125M for back pain neuromod implant
Feb 28, 2024 12:07pm
FDA expands OK for Boston Sci WaveWriter spinal cord stimulators
Feb 6, 2024 12:28pm
Boston Sci bids $850M for nerve ablation tech maker Relievant
Sep 19, 2023 10:43am
FDA approves Abbott's spinal cord stimulators for back pain
May 16, 2023 12:51pm
